Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy Musiek

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of the American Academy of Dermatology|December 19, 2012
Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphomaSara Samimi, Kelly Morrissey, Sasha Anshelevich, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endotheliumBo Lu, Ling Geng, Amy Musiek, et al.
Journal of the American Academy of Dermatology|December 3, 2014
Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implicationsAndy C Hsi, Sena J Lee, Ilana S Rosman, et al.
American Journal of Clinical Dermatology|March 3, 2021
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell LymphomaEllen J Kim, Joan Guitart, Christiane Querfeld, et al.
American Journal of Clinical Dermatology|March 16, 2022
Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell LymphomaEllen J Kim, Joan Guitart, Christiane Querfeld, et al.
Journal of the American Academy of Dermatology|February 25, 2020
Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational studyEllen J Kim, Larisa Geskin, Joan Guitart, et al.
Dermatologic Therapy|June 13, 2022
Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphomaMartine Bagot, Stéphane Dalle, Lubomir Sokol, et al.
The Journal of Investigative Dermatology|July 22, 2018
Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus ErythematosusAnniek Zaalberg, Sara Moradi Tuchayi, Amir H Ameri, et al.
Leukemia & Lymphoma|June 9, 2011
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld, Timothy M Kuzel, Youn H Kim, et al.
Journal of the American Academy of Dermatology|April 20, 2020
United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemicJohn A Zic, Weiyun Ai, Oleg E Akilov, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of the American Academy of Dermatology|December 19, 2012
Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphomaSara Samimi, Kelly Morrissey, Sasha Anshelevich, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endotheliumBo Lu, Ling Geng, Amy Musiek, et al.
Journal of the American Academy of Dermatology|December 3, 2014
Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implicationsAndy C Hsi, Sena J Lee, Ilana S Rosman, et al.
American Journal of Clinical Dermatology|March 3, 2021
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell LymphomaEllen J Kim, Joan Guitart, Christiane Querfeld, et al.
American Journal of Clinical Dermatology|March 16, 2022
Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell LymphomaEllen J Kim, Joan Guitart, Christiane Querfeld, et al.
Journal of the American Academy of Dermatology|February 25, 2020
Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational studyEllen J Kim, Larisa Geskin, Joan Guitart, et al.
Dermatologic Therapy|June 13, 2022
Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphomaMartine Bagot, Stéphane Dalle, Lubomir Sokol, et al.
The Journal of Investigative Dermatology|July 22, 2018
Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus ErythematosusAnniek Zaalberg, Sara Moradi Tuchayi, Amir H Ameri, et al.
Leukemia & Lymphoma|June 9, 2011
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld, Timothy M Kuzel, Youn H Kim, et al.
Journal of the American Academy of Dermatology|April 20, 2020
United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemicJohn A Zic, Weiyun Ai, Oleg E Akilov, et al.
Pageof 4